Search Results for "vol"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vol. Results 131 to 140 of 1514 total matches.
FK 506 - An Investigational Immunosuppressant
The Medical Letter on Drugs and Therapeutics • Oct 04, 1991 (Issue 854)
).
The Medical Letter, Vol. 33 (Issue 854) October 4, 1991, p. 94
Copyright The Medical Letter
UNAUTHORIZED ...
FK 506 (Fujisawa), an immunosuppressant similar in activity to cyclosporine (Sandimmune - Medical Letter 25:77, 1983), is currently under investigation in the USA, Europe, and Japan for prevention of organ transplant rejection.
Drug Treatment of Cardiac Arrest
The Medical Letter on Drugs and Therapeutics • Mar 20, 1992 (Issue 866)
).
The Medical Letter, Vol. 34 (Issue 866) March 20, 1992, p. 30
Copyright The Medical Letter
UNAUTHORIZED ...
Cardiac arrest may be due to tachyarrhythmias, bradyarrhythmias, or asystole. Without treatment, permanent damage to the cerebral cortex usually begins within five minutes and is complete in ten. After cardiopulmonary resuscitation (CPR) has been started and electrical defibrillation, when indicated, has been applied, drugs may help promote recovery.
Topical Treatment for Bacterial Vaginosis
The Medical Letter on Drugs and Therapeutics • Nov 27, 1992 (Issue 884)
tolerated, for treatment of bacterial vaginosis.
(continued on next page)
The Medical Letter, Vol. 34 ...
A 0.75% vaginal gel formulation of metronidazole (MetroGel-Vaginal - Curatek) and a 2% vaginal cream formulation of clindamycin phosphate (Cleocin - Upjohn) were recently approved by the US Food and Drug Administration for treatment of bacterial vaginosis. Seven days' treatment with oral metronidazole, 500 mg b.i.d., has been the usual treatment for this condition, with oral clindamycin, 300 mg b.i.d., as an alternative (JL Thomason et al, Am J Obstet Gynecol, 165:1210, 1991).
Paroxetine for Treatment of Depression
The Medical Letter on Drugs and Therapeutics • Mar 19, 1993 (Issue 892)
, the patient’s response to the starting dosage may not be
The Medical Letter, Vol. 35 (Issue 892) March 19, 1993 ...
Paroxetine (Paxil - SmithKline Beecham), a new selective serotonin reuptake inhibitor (SSRI), is now available in the USA. Two other SSRIs, fluoxetine (Prozac - Medical Letter, 30:45, 1988; 32:83, 1990) and sertraline (Zoloft - Medical Letter, 34:47, 1992), were approved previously.
Alpha-Galactosidase to Prevent Gas
The Medical Letter on Drugs and Therapeutics • Apr 02, 1993 (Issue 893)
Letter consultant reported
The Medical Letter, Vol. 35 (Issue 893) April 2, 1993, pp. 29-30
Copyright ...
The enzyme alpha-galactosidase (Beano - AkPharma), derived from a mold and classified as a food, is sold without presecription in pharmacies and food stores. The manufacturer recommends taking the anzyme to decrease intestinal gas producted by eating the high-fiber diets now widely recommended in the USA.
OncoScint for Detetion of Disseminated Colorectal and Ovarian Cancer
The Medical Letter on Drugs and Therapeutics • Jun 11, 1993 (Issue 898)
1993).
The Medical Letter, Vol. 35 (Issue 898) June 11, 1993, pp. 52-53
Copyright The Medical ...
Indium 111 In-satumomab pendetide (CYT-103, OncoScint CR/OV Kit - Cytogen), a new intravenous imaging agent, has been approved by the US Food and Drug Administration for detection of extrahepatic spread of colorectal and ovarian tumors.
Shade UVAGuard - A Second Broad-Spectrum Sunscreen
The Medical Letter on Drugs and Therapeutics • Jun 11, 1993 (Issue 898)
to 4.8; the mean PPF for Shade UVAGuard
The Medical Letter, Vol. 35 (Issue 898) June 11, 1993, pp. 53-54 ...
In 1989, Photoplex (Allergan Herbert), a combination of the dibenzoyl methane avobenzone (Parsol 1789) and the aminobenzoic acid (PABA) ester padimate O, was the first 'broad spectrum' sunscreen to become available in the USA (Medical Letter, 31:59, 1989). Now, Shade UVAGuard (Schering-Plough), a similar product, has been approved by the US Food and Drug Administration; it also contains avobenzone, plus the benzophenone oxybenzone and octyl methoxycinnamate.
Drugs for Acute Spinal Cord Injury
The Medical Letter on Drugs and Therapeutics • Aug 06, 1993 (Issue 902)
degree of recovery; in terms of initially paralyzed muscle groups, treated
The Medical Letter, Vol. 35 ...
The well-publicized recovery from paralysis of a professional football player has recently focused attention on the growing use of drugs to minimize the effects of spinal cord injury. Methylprednisolone sodium succinate (Solu-Medrol - Upjohn), commercially available in the USA for intravenous treatment of transplant rejection and various inflammatory and auto-immune disorders, and GM-1 ganglioside, commercially available in Italy (Sygen - Fidia) but not in the USA, are now widely used in patients with spinal cord injury.
Radioactive Strontium-89 for Painful Bone Metastases
The Medical Letter on Drugs and Therapeutics • Oct 29, 1993 (Issue 908)
if necessary, but the risk of myelotoxicity is cumulative.
The Medical Letter, Vol. 35 (Issue 908) October 29 ...
Strontium-89 chloride was recently approved for marketing by the US Food and Drug Administration. It is offered for relief of pain caused by metastatic bone lesions
Home Testing of Cholesterol
The Medical Letter on Drugs and Therapeutics • Sep 30, 1994 (Issue 932)
the slide, and determining where the purple column ended.
The Medical Letter, Vol. 36 (Issue 932) September ...
The new Advanced Care Cholesterol Test (Johnson & Johnson) now being advertised to the general public encourages patients to test their own serum cholesterol concentrations. Approved by the US Food and Drug Administration, this product is available in pharmacies without a prescription at a cost of about $20 for a single determination.